Two smart connected insulin pens from Novo Nordisk have been made available on prescription in the UK. The NovoPen 6 and NovoPen Echo Plus pens from the Danish multinational pharmaceutical firm not only inject insulin, but also record how much insulin and when the dose was administered. Such data will help healthcare professionals to attain a more accurate picture of their patients.
Emma Wilmot, consultant diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust, said: “Integrating innovative technology as a routine part of diabetes care is an important step to improve diabetes care. Novo Nordisk’s smart connected pens are an example of how technology can support people living with diabetes to gain greater insight into the management of their diabetes, on their journey to becoming experts in their diabetes."
"In my clinic, the opportunity to view daily insulin data will allow me to better support the individual with diabetes to achieve their goals. It will allow for more tailored and informed advice on optimisation of glucose levels, with the ultimate goal of improving future outcomes.”
The pens, which are reusable, have been found to reduce the amount of missed doses by people living with type 1 diabetes. The device can also provide patients with up to two extra hours of improved glucose levels per day.
Pinder Sahota, general manager, Novo Nordisk UK, commented: “We believe digital innovation of devices and treatments has the potential to transform people’s lives and help alleviate the daily burden of living with diabetes. Our smart connected insulin pens aim to empower people to better understand their diabetes management, have more informed conversations with their doctor and ultimately improve their blood glucose control.”